COVID-19 Rapid Diagnostic Test Market Analysis & Forecast: 2026-2033

COVID-19 Rapid Diagnostic Test Market Size and Share Analysis - 2026 To 2033

COVID-19 rapid diagnostic tests are in vitro diagnostic tools designed to detect current or past infection with SARS-CoV-2 within a short period, typically 15–30 minutes. These tests include antigen, molecular, and antibody-based assays, with antigen tests being the most widely used for rapid screening. They are commonly performed in hospitals, clinics, pharmacies, workplaces, community testing centers, and home settings to support timely diagnosis, infection control, and public health surveillance. Rapid diagnostic tests generally require minimal laboratory infrastructure, making them suitable for decentralized and point-of-care testing.

Key Statistics at a Glance

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

The global COVID-19 rapid diagnostic test market size is estimated to reach USD 4,900 Mn in 2026 and is projected to touch a valuation of USD 6,600.0 Mn by 2033, growing at a CAGR of 4.3% during the forecast period (2026–2033). This is attributable to continued demand for rapid point-of-care diagnostics, expanding infectious disease surveillance programs, and increasing preparedness for future pandemics.

Key Takeaways from the COVID-19 Rapid Diagnostic Test Market Report

• Reagents & kits are expected to lead the market with a share of 84% in 2026 due to their single-use nature as well as continuous testing demand. For instance, the U.S. FDA recommends at-home antigen testing at least twice over 3 days for symptomatic individuals, increasing the consumption of disposable reagents & kits.
• Antigen-based testing is slated to account for the largest market share of 49% in 2026 because of its low cost, rapid results, and widespread use in point-of-care and self-testing settings. For instance, an NIH-supported study found that rapid antigen tests provide results in about 15 minutes (versus up to a few days for laboratory PCR tests), enabling widespread point-of-care and at-home testing.
• North America is forecast to dominate the COVID-19 rapid diagnostic test industry with a share of 35% in 2026 due to advanced healthcare infrastructure, high healthcare spending, and widespread adoption of rapid diagnostic testing. For instance, U.S. healthcare spending reached US$5.3 trillion in 2024 (18.0% of GDP), supporting extensive adoption of advanced diagnostic technologies, including rapid tests.

COVID-19 Rapid Diagnostic Test Market Overview

The global COVID-19 rapid diagnostic test market is expected to register moderate growth during the forecast period. This is primarily due to rising need for rapid and decentralized testing in healthcare settings, growing preparedness for future infectious disease outbreaks, and increasing adoption of point-of-care diagnostic solutions.

Although routine COVID-19 testing demand has declined following the pandemic peak, sustained surveillance programs, periodic infection waves, and government initiatives to strengthen public health infrastructure continue to support market growth. In addition, technological advancements in rapid antigen and molecular diagnostic tests and expanding applications in hospitals, clinics, pharmacies, workplaces, and home-based testing are expected to support market expansion during the forecast period.

Expansion of home and self-testing is also providing stimulus for the expansion of COVID-19 rapid diagnostic test market. There is a shift towards at-home rapid testing kits as modern consumers prefer convenience and instant results. Increasing availability of OTC (over-the-counter) antigen test kits also supports this transition.

Technological advancements in test accuracy and speed are also driving market growth by improving reliability and usability. Enhanced antigen test sensitivity and specificity, along with rapid molecular (NAAT/isothermal) tests, enable quicker and more accurate detection. Integration of digital readers and AI-based interpretation reduces errors, while multiplex tests detecting COVID-19, flu, and RSV increase clinical utility and broaden adoption across healthcare settings.

Segmental Insights 

To learn more about this report, Request Free Sample

Which Product Type Dominates the COVID-19 Rapid Diagnostic Test Market?

Reagents & Kits to Dominate the Market with 84%

According to Coherent Market Insights' latest COVID-19 rapid diagnostic test market analysis, reagents & kits are set to lead the market, accounting for a revenue share of 84% in 2026. This dominance is attributable to their recurring consumption, widespread use in point-of-care and laboratory testing, and high testing volumes. In addition, continuous demand for replacement supplies and ongoing regulatory approvals and product launches are expected to also strengthen their market position by expanding testing accessibility and diagnostic accuracy.

Which Test Type Accounts for the Largest Share in COVID Rapid Diagnostic Test Market?

Antigen-based Testing Takes the Lead with Nearly Half of the Market Share

To learn more about this report, Request Free Sample

By test type, antigen-based testing is projected to lead the global COVID-19 rapid diagnostic test market, holding a share of 49% in 2026. This is mostly due to its rapid turnaround time, low cost, ease of use at the point of care, and widespread adoption for large-scale screening in hospitals, clinics, workplaces, schools, airports, and home settings.

Antigen tests require minimal laboratory infrastructure and provide results within 15–30 minutes, making them the preferred choice for frequent testing and outbreak management. In addition, continuous improvements in test sensitivity and availability of over-the-counter self-test kits have also strengthened their adoption across both developed and emerging healthcare markets.

For example, in December 2025, the WHO prequalified its first two COVID-19 rapid antigen tests. The organization emphasized that rapid antigen tests remain essential for outbreak detection, particularly in primary care and community settings, owing to their affordability, rapid turnaround time (15–30 minutes), and suitability for point-of-care use. This supports the growing use of antigen-based testing for decentralized COVID-19 screening.

COVID-19 Rapid Diagnostic Test Market Growth Drivers

Continued COVID-19 Surveillance

Although COVID-19 has become endemic in many countries, governments, hospitals, and healthcare providers continue routine testing to monitor seasonal infection waves and emerging variants. This sustained surveillance maintains consistent demand for rapid diagnostic tests, supporting the growth of the COVID-19 rapid diagnostic test market.

COVID-19 Rapid Diagnostic Test Market Opportunities

Growing Adoption of Point-of-Care (POC) Testing

Rising preference for POCT is expected to create lucrative growth opportunities for the COVID-19 rapid diagnostic test market during the forthcoming period. Rapid diagnostic tests provide results within 15–30 minutes, enabling immediate clinical decisions. Their convenience has increased adoption in emergency departments, clinics, pharmacies, airports, workplaces, and community healthcare settings.

COVID-19 Rapid Diagnostic Test Market Trends

Shift Toward Multiplex Respiratory Testing: Rising adoption of multiplex respiratory tests capable of detecting SARS-CoV-2, influenza A/B, and RSV from a single sample is a key growth-shaping market trend. Healthcare providers in the contemporary world are increasingly shifting from COVID-19-only tests to multiplex assays that simultaneously detect SARS-CoV-2, influenza A/B, and RSV from a single sample.

Rising need for faster differential diagnosis due to the similarity in symptoms of respiratory infections, along with improved clinical decision-making and more efficient testing workflows, is propelling the shift toward this approach. Manufacturers are thus increasingly launching and expanding multiplex rapid diagnostic platforms.

For example, ACON Laboratories received FDA 510(k) clearance for its Flowflex Plus RSV + Flu A/B + COVID Home Test in October 2025. This OTC rapid antigen test is a lateral flow immunoassay intended for the rapid, simultaneous qualitative detection and differentiation of respiratory syncytial virus (RSV), influenza A and B, and SARS-CoV-2 (COVID-19) antigens.

Current Events and Their Impact on the COVID-19 Rapid Diagnostic Test Market

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Regional Insights

To learn more about this report, Request Free Sample

North America Remains at the Epicenter of COVID-19 Rapid Diagnostic Test Market Growth

North America is expected to account for around 35% of the global COVID-19 rapid diagnostic test market share in 2026. This dominance is attributed to advanced diagnostic infrastructure, strong government support for infectious disease surveillance, and rising adoption of rapid point-of-care testing across hospitals, clinics, pharmacies, and home settings.

High testing demand is playing a key role in boosting North America COVID-19 rapid diagnostic test market. According toThis increasing use of diagnostic testing is expected to boost sales of COVID-19 rapid diagnostic tests in the region during the forecast period.

Asia Pacific Remains COVID-19 Rapid Diagnostic Test Market Trends

Asia Pacific is anticipated to remain a highly lucrative market for manufacturers of COVID-19 rapid diagnostic test products during the forecast period. This is mostly due to expanding healthcare infrastructure, increasing government investments in infectious disease surveillance, rising awareness of early diagnosis, and growing availability of affordable rapid diagnostic tests across nations like China, India, and Japan.

Government-led expansion of diagnostic capacity is boosting Asia Pacific COVID-19 rapid diagnostic test market growth. For example, in 2025, a WHO-backed multi-country initiative supported by the Pandemic Fund was launched across South-East Asia to strengthen diagnostic readiness as well as expand rapid testing infrastructure, reinforcing regional capacity for early detection and outbreak response.

COVID-19 Rapid Diagnostic Test Market Outlook – Country-wise

U.S. COVID-19 Rapid Diagnostic Test Market Forecast

The United States is anticipated to remain a leading market for COVID-19 rapid diagnostic testing products during the forecast period. This is due to increasing government support for infectious disease surveillance, widespread availability of rapid self-testing kits, and growing adoption of point-of-care diagnostics across hospitals, pharmacies, and home healthcare settings. Similarly, ongoing innovation in antigen-based and molecular point-of-care testing is set to boost market growth in the nation during the forecast period.

China COVID-19 Rapid Diagnostic Test Market Trends

China's COVID-19 rapid diagnostic test market is expected to witness steady growth during the forecast period. This is attributed to expanding healthcare infrastructure, increasing investments in diagnostic technologies, strong domestic manufacturing capabilities, and continued government focus on infectious disease monitoring and public health preparedness. In addition, rapid expansion of digital health ecosystems, including mobile-based self-testing platforms and AI-enabled diagnostic interpretation tools, is improving accessibility and turnaround time for test results across urban and rural populations.

Who are the Major Companies in the COVID-19 Rapid Diagnostic Test Market?

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Key Strategies Adopted by Industry Players

Top manufacturers of anticoagulant reversal drugs are adopting various organic and inorganic strategies to boost their sales as well as gain a competitive edge in the industry. These include new product launches and approvals, clinical trials, investments in R&D, mergers, acquisitions, distribution agreements, partnerships, collaborations, and joint ventures.

• In October 2025, ACON Laboratories announced that it had received FDA 510(k) clearance for its Flowflex Plus RSV + Flu A/B + COVID Home Test. It is an OTC rapid antigen test that can be administered at home by consumers.
• In August 2025, Roche Diagnostics received U.S. FDA 510(k) clearance for its cobas Respiratory 4-flex assay, an automated multiplex PCR test utilizing TAGS (Temperature-Activated Generation of Signal) technology. The assay is designed for the simultaneous detection and differentiation of SARS-CoV-2, Influenza A, Influenza B, and RSV on cobas 5800, 6800, and 8800 systems.
• In February 2023, the U.S. FDA granted Emergency Use Authorization to Lucira Health’s COVID-19 & Flu Home Test, the first over-the-counter at-home molecular test that can detect and differentiate COVID-19 and Influenza A/B. This approval marked an important shift toward multiplex rapid diagnostic testing for respiratory infections.

Market Report Scope

Analyst Opinion (Expert Opinion)

• Rapid tests have become a core part of decentralized diagnostics. Their ability to deliver results in 15–30 minutes without laboratory infrastructure makes them ideal for home testing, pharmacies, workplaces, airports, schools, and remote healthcare settings, supporting continued market demand.
• COVID-19 testing remains clinically relevant despite the pandemic emergency ending. The WHO continues to recommend rapid antigen tests for symptomatic testing, outbreak investigations, screening, and self-testing, highlighting their ongoing role in infectious disease management. This supports long-term product adoption and recurring procurement by healthcare systems.
• Performance standards continue to improve. WHO recommends antigen rapid diagnostic tests with ≥80% sensitivity and ≥97% specificity compared with molecular tests, encouraging manufacturers to develop higher-quality products.
• In December 2025, WHO granted its first-ever prequalification to two COVID-19 rapid antigen tests, reinforcing the importance of reliable rapid diagnostics even after the global public health emergency. This improves global procurement opportunities and accelerates adoption in international health programs.

Market Segmentation

• By Product Type Insights ( Revenue, USD Mn, 2021 - 2033)
  • Instruments
  • Reagents and Kits
• By Sample Type Insights ( Revenue, USD Mn, 2021 - 2033)
  • Nasopharyngeal swab
  • Oropharyngeal swab
  • Nasal swab
  • Osteosarcoma
  • Blood
  • Others
• By Test Type Insights ( Revenue, USD Mn, 2021 - 2033)
  • Molecular Testing
  • Antigen based Testing
  • Antibody Testing
  •  Others
• By End User Insights ( Revenue, USD Mn, 2021 - 2033)
  • Hospitals
  • Laboratories and Diagnostic Centers
  • Others
• By Region Insights ( Revenue, USD Mn, 2021 - 2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • North Africa
    • Central Africa
    • South Africa

Sources

Primary Research interviews

• Manufacturers of COVID-19 rapid diagnostic tests
• Clinical laboratory professionals
• Hospital procurement managers
• Infectious disease specialists
• Point-of-care testing experts
• Diagnostic distributors and suppliers
• Regulatory and quality assurance professionals

Databases

• PubMed
• Scopus
• Embase
• ClinicalTrials.gov
• Europe PMC
• WHO Global Health Observatory
• OECD Health Statistics

Magazines

• Medical Laboratory Observer
• Clinical Lab Products
• Laboratory Medicine
• Healthcare Purchasing News
• Diagnostics World News

Journals

• The Lancet Infectious Diseases
• Journal of Clinical Microbiology
• Clinical Infectious Diseases
• Diagnostic Microbiology and Infectious Disease
• Journal of Medical Virology
• BMJ Global Health

Newspapers

• The New York Times
• The Wall Street Journal
• Financial Times
• The Guardian
• The Hindu
• Business Standard

Associations

• Association for Diagnostics & Laboratory Medicine (ADLM)
• Infectious Diseases Society of America (IDSA)
• American Society for Microbiology (ASM)
• European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
• International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)

Public Domain sources

• World Health Organization (WHO)
• U.S. Food and Drug Administration (FDA)
• U.S. Centers for Disease Control and Prevention (CDC)
• European Centre for Disease Prevention and Control (ECDC)
• European Medicines Agency (EMA)
• National Institutes of Health (NIH)
• UK Health Security Agency (UKHSA)
• FIND (Foundation for Innovative New Diagnostics)
• Our World in Data
• World Bank
• United Nations (UN)

Proprietary Elements

• CMI Data Analytics Tool
• Proprietary CMI Existing Repository of information for last 8 years